関連ニュース

Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both

Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript